# DEN240064: CT-132

- Pathway: De Novo (Direct)
- Applicant: Click Therapeutics, Inc.
- Decided: Apr 11, 2025 after 150 days
- Product code: SEE (Computerized Behavioral Therapy Device For Migraine)
- Device class: 2
- Regulation: 21 CFR 882.5806
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
No predicates in its family tree.
No later device cites it as a predicate yet.
0 of 1 device in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- None. De Novo decisions do not claim a predicate device.

## Indications for use
CT-132 is indicated for the preventive treatment of episodic migraine in patients 18 years of age and older. It is intended for adjunctive use alongside acute and/or other preventive treatments for migraine.

Source page: https://510kreport.com/device/DEN240064
Methodology: https://510kreport.com/methodology